Because of a preconceived notion that eliminating reactive metabolite (RM) formation with
new drug candidates could mitigate the risk of idiosyncratic drug toxicity, the potential for RM …

Iron-Chelating Therapy for Transfusional Iron Overload | New England Journal of Medicine Skip
to main content The New England Journal of Medicine homepage Advanced Search SEARCH …

The prevalence rate of thalassemia, which is endemic in Southeast Asia, the Middle East,
and the Mediterranean, exceeds 100,000 live births per year. There are many genetic …

Acyl glucuronidation is the major metabolic conjugation reaction of most carboxylic acid
drugs in mammals. The physiological consequences of this biotransformation have been …

Thalassemia bone disease is a common and severe complication of thalassemia—an
inherited blood disorder due to mutations in the α or β hemoglobin gene. In its more severe …

Introduction: Oxidative stress (caused by excess iron) can result in tissue damage, organ
failure and finally death, unless treated by iron chelators. The causative factor in the etiology …

Deferiprone (L1) was originally designed, synthesised and screened in vitro and in vivo in
1981 by Kontoghiorghes GJ following his discovery of the novel alpha-ketohydroxypyridine …

Iron overload occurs when iron intake is increased over a sustained period of time, either as
a result of red blood cell transfusions or increased absorption of iron through the …

Over the past four decades, there have been dramatic improvements in survival for patients
with thalassemia major due in large measure to improved iron chelators. Two chelators are …

It is estimated that by 2050, bacterial infections will cause 1.8 million more deaths than
cancer annually, and the current lack of antibiotic drug discovery is only exacerbating the …